Trial Profile
A Phase II Study Evaluating Bi-weekly Dosing of Gemcitabine Plus Nab-Paclitaxel in the First Line Treatment of Surgically Unresectable/Metastatic Pancreatic Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Dec 2017
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Paclitaxel (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 02 Mar 2015 Status changed from recruiting to discontinued, according to ClinicalTrials.gov record.
- 16 May 2013 New trial record